HC Wainwright Has Lowered Expectations for Savara (NASDAQ:SVRA) Stock Price

Savara (NASDAQ:SVRA – Get Free Report) had its price objective dropped by equities researchers at HC Wainwright from $10.00 to $9.00 in a report issued on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright‘s price target would indicate a potential upside of 111.27% from the company’s previous close. HC Wainwright also issued estimates for Savara’s FY2029 earnings at $0.06 EPS and FY2030 earnings at $0.23 EPS.

A number of other brokerages also recently issued reports on SVRA. Citigroup reaffirmed a “market outperform” rating on shares of Savara in a research note on Wednesday, October 7th. Royal Bank Of Canada set a $10.00 price target on shares of Savara in a research report on Wednesday, October 7th. JPMorgan Chase & Co. initiated coverage on shares of Savara in a report on Wednesday, October 7th. They issued an “overweight” rating and a $12.00 price objective for the company. Wall Street Zen cut shares of Savara from a “hold” rating to a “sell” rating in a research report on Sunday, October 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research report on Thursday, October 15th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $10.14.

Get Our Latest Analysis on Savara

Savara Price Performance

SVRA stock opened at $4.26 on Friday. Savara has a 1 year low of $4.00 and a 1 year high of $7.01. The company has a debt-to-equity ratio of 0.28, a current ratio of 8.55 and a quick ratio of 8.55. The firm has a market capitalization of $939.86 million, a PE ratio of -6.98 and a beta of 0.32. The business has a 50 day simple moving average of $4.86 and a 200-day simple moving average of $5.31.

Savara (NASDAQ:SVRA – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.01. Equities research analysts anticipate that Savara will post -0.67 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of SVRA. Quarry LP lifted its holdings in shares of Savara by 6,524.4% in the 3rd quarter. Quarry LP now owns 11,924 shares of the company’s stock worth $62,000 after acquiring an additional 11,744 shares during the last quarter. Jump Financial LLC purchased a new position in shares of Savara during the 3rd quarter worth approximately $720,000. Marshall Wace LLP increased its holdings in Savara by 2.1% in the 3rd quarter. Marshall Wace LLP now owns 6,386,775 shares of the company’s stock valued at $32,956,000 after purchasing an additional 129,786 shares during the last quarter. Nantahala Capital Management LLC increased its holdings in Savara by 2.3% in the 3rd quarter. Nantahala Capital Management LLC now owns 7,137,159 shares of the company’s stock valued at $36,828,000 after purchasing an additional 160,349 shares during the last quarter. Finally, Nan Fung Trinity HK Ltd. increased its holdings in Savara by 1,088.3% in the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 1,842,350 shares of the company’s stock valued at $9,507,000 after purchasing an additional 1,687,310 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Top Savara Stories

These are some of the SVRA stories that stood out recently:

  • Positive Sentiment: HC Wainwright maintained a Buy rating while lowering its price target from $10 to $9, still implying substantial potential upside from the quoted share price. HC Wainwright rating
  • Negative Sentiment: The FDA told Savara it would not act on the molgramostim BLA by the PDUFA date. The missed review deadline is the key near-term negative catalyst, postponing regulatory clarity for the drug candidate. Savara FDA update Reuters report

Savara Company Profile

(Get Free Report)

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.

See Also

Analyst Recommendations for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.